Last reviewed 2026-04-19 · How we verify

OKN4395

Epkin · Phase 1 active Small molecule

At a glance

Generic name	OKN4395
Sponsor	Epkin
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OKN4395 CI brief — competitive landscape report
OKN4395 updates RSS · CI watch RSS
Epkin portfolio CI